Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials

Edward K. Avila*, Marc Chamberlain, David Schiff, Jaap C. Reijneveld, Terri S. Armstrong, Roberta Ruda, Patrick Y. Wen, Michael Weller, Johan A.F. Koekkoek, Sandeep Mittal, Yoshiki Arakawa, Ali Choucair, Jorge Gonzalez-Martinez, David R. MacDonald, Ryo Nishikawa, Aashit Shah, Charles J. Vecht, Paula Warren, Martin J. Van Den Bent, Lisa M. DeAngelis

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy. A review of the current literature regarding seizure assessment for low-grade glioma patients reveals a heterogeneous manner in which seizure response has been reported. There is a need for a systematic approach to seizure assessment and its influence on health-related quality-of-life outcomes in patients enrolled in low-grade glioma therapeutic trials. In view of the need to have an adjunctive metric of tumor response in these patients, a method of seizure assessment as a metric in brain tumor treatment trials is proposed.

Original languageEnglish
Pages (from-to)12-21
Number of pages10
Issue number1
Publication statusPublished - 2017

Cite this